Clinical Trials Directory

People in this study will be placed into one of three groups. They will receive either L19IL2, L19TNF, or both L19IL2 and L19TNF. These treatments are given once a week for up to 4 weeks, or until the person’s tumors are gone.

L19IL2/L19TNF

We are doing this study to find the most effective, safe dose of an experimental drug called CLN-049 (the study drug) for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

We are doing this study to find out if the experimental combination and use of the drugs nivolumab and relatlimab can provide a benefit for people who are newly diagnosed with isocitrate dehydrogenase (IDH) wildtype glioblastoma (ndGBM).

Participants will receive either the study vaccine or a placebo during pregnancy. Mothers will be followed until about 6 months after delivery, and babies will be followed until 12 months of age through study visits and phone calls. Some babies may also join an optional part of the study that includes routine childhood vaccines and extra study visits.

We are doing this study to find out if continued use of an experimental drug called bomedemstat (the study drug) can provide an extended benefit for people with myeloproliferative neoplasms. We are enrolling people who have been in a previous study using the study drug and received a positive benefit.

We are doing this study to find out if an investigational drug called fostamatinib (the study drug) is beneficial for cGvHD when it is used in combination with a standard of care drug, ruxolitinib. We want to know if the study drug can improve relief from cGvHD symptoms.